Semaglutide Brand Name: Ozempic, Wegovy & Compounded Alternatives

Last reviewed: May 27, 2026

Last updated: May 27, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide is marketed under three main brand names depending on indication: Ozempic (type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (oral tablet). Each formulation and brand carries distinct FDA approvals, dosing schedules, and clinical contexts that affect access and appropriateness for individual patients.

For patients exploring semaglutide therapy, brand name alone does not determine whether a medication aligns with your health goals, baseline metabolic profile, or genetic predispositions in peptide signaling pathways. PlexusDx supports a precision-wellness approach: understanding what each brand represents clinically, evaluating compounded alternatives, and incorporating biomarker context to guide an informed provider conversation.

The Three FDA-Approved Semaglutide Brands and Their Clinical Roles

Ozempic (semaglutide injection) is FDA-approved for type 2 diabetes management in adults. Dosing starts at 0.25 mg weekly and titrates up to a maintenance dose, with demonstrated A1C reduction of 1.5–1.8% in clinical trials. It is not approved for weight loss in non-diabetic patients.

Wegovy (semaglutide injection) is FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities. Dose escalation occurs over 16 weeks to a 2.4 mg maintenance dose, with mean weight loss of 15% in Phase 3 trials compared to placebo's 2.4%. This formulation and indication differ from Ozempic despite identical active drug.

Rybelsus (oral semaglutide tablets) is FDA-approved for type 2 diabetes and must be taken on an empty stomach 30 minutes before food or drink. Absorption is approximately 1% bioavailability, requiring higher doses (7–14 mg daily) than injected formulations. Rybelsus is not indicated for weight loss in non-diabetic populations.

Branded vs. Compounded Semaglutide: Clinical and Access Considerations

Branded semaglutide products are FDA-approved and manufactured by Novo Nordisk under strict pharmaceutical standards. Compounded semaglutide is prepared by licensed 503A compounding pharmacies and is not FDA-approved but may be prescribed off-label by qualified providers. Understanding the distinctions—manufacturing oversight, cost, availability, and clinical evidence base—is essential for informed decision-making.

Factor	Branded Semaglutide (Ozempic/Wegovy/Rybelsus)	Compounded Semaglutide
Regulatory Status	FDA-approved with defined indication	Compounded by 503A pharmacies; not FDA-approved
Manufacturing	Novo Nordisk pharmaceutical-grade production	Licensed compounding pharmacy oversight
Cost Range	Typically $900–$1,200+ monthly after insurance	PlexusDx pricing $149 monthly
Availability	Subject to supply chain and insurance coverage	Potentially broader access without insurance barriers
Clinical Evidence	Extensive Phase 3 trial data for approved indications	Evidence base relies on branded formulation studies
Off-Label Use	Requires provider discretion; limited insurance coverage	May expand off-label options with provider guidance

Why Brand Name and Clinical Indication Matter for Your Treatment Plan

The FDA approval pathway for a semaglutide brand determines its labeled indication, approved dosing schedule, and supported clinical population. Ozempic's diabetes indication differs from Wegovy's weight-management indication, affecting insurance coverage, provider comfort, and baseline health expectations when initiating therapy.

Off-label prescribing of Ozempic or Rybelsus for weight loss occurs clinically but lacks FDA labeling support and may not be covered by insurance. Understanding whether your provider is recommending a branded product for its approved indication or an off-label use informs realistic expectations, potential side effects, and cost responsibility. Compounded semaglutide allows providers greater prescribing flexibility while maintaining clinical oversight through a licensed pharmacy.

Genetic and Biomarker Context: Personalizing Semaglutide Selection

Individual variation in GLP-1 receptor signaling, baseline glucose metabolism, and weight regulation involves multiple genetic pathways. Variants in GLP1R (rs6923761), GIPR (rs1800437), and FTO (rs9939609) may correlate with metabolic predispositions that inform whether semaglutide therapy aligns with your physiological profile—regardless of brand or formulation chosen.

PlexusDx's Precision Peptide Genetic Test examines these peptide pathway predispositions to provide context for a more targeted provider conversation. The test does not predict exact medication response or guarantee outcomes, but may help clarify which patients' metabolic profiles suggest stronger alignment with GLP-1 receptor agonist therapy. This biomarker insight can support personalized dosing, formulation selection, and realistic expectations for weight or glucose outcomes.

Safety Considerations and Who Should Evaluate Semaglutide Therapy

Semaglutide—regardless of brand—carries risks including pancreatitis, gallbladder disease, dehydration, and thyroid-related adverse events. Contraindications include personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. A qualified healthcare provider must evaluate baseline kidney function, diabetic retinopathy status, and medication interactions before initiating therapy.

Patients with type 2 diabetes, obesity, or prediabetes combined with cardiovascular risk factors are common candidates for semaglutide therapy. However, off-label use in non-diabetic individuals requires careful provider assessment, realistic goal-setting, and ongoing monitoring. Whether you choose a branded semaglutide or a compounded alternative, medical supervision, regular lab review, and adjustment protocols are non-negotiable safeguards.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that semaglutide brand selection is only one component of precision-wellness decision-making. Genetic predispositions in peptide signaling pathways—assessed via the Precision Peptide Genetic Test—may help provide additional context about your metabolic readiness for GLP-1 receptor agonist therapy. This insight should be interpreted collaboratively with your healthcare provider, not as a standalone predictor of medication success.

The Precision Peptide Genetic Test examines variants associated with glucose regulation, appetite signaling, and weight metabolism (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313). These predispositions can support a more informed conversation about whether semaglutide—whether branded or compounded—aligns with your baseline physiology. The test costs $99 as an add-on or $298 standalone and complements clinical evaluation, not replaces it.

If you are evaluating semaglutide options through PlexusDx, combining genetic context with provider guidance and cost-effectiveness analysis creates a more holistic decision framework. Our licensed 503A compounding pharmacies offer compounded semaglutide at $149 monthly, enabling broader access while maintaining clinical oversight. A qualified provider should review your genetic results, clinical history, and treatment goals to determine the most appropriate formulation and dosing plan.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the difference between Ozempic and Wegovy if they are both semaglutide?

Ozempic is FDA-approved for type 2 diabetes at starting doses of 0.25 mg weekly. Wegovy is FDA-approved for weight management in non-diabetic patients, with dose escalation to 2.4 mg weekly. While the active drug is identical, the approved indications, dosing schedules, and clinical evidence bases differ, affecting insurance coverage and prescri...

Is Rybelsus (oral semaglutide) as effective as injected semaglutide?

Rybelsus has approximately 1% oral bioavailability, requiring higher doses (7–14 mg daily) than injected formulations. Phase 3 trials demonstrate comparable A1C reduction in type 2 diabetes, but GI side effects and adherence challenges may differ. It is not FDA-approved for weight loss.

Why is compounded semaglutide significantly cheaper than branded versions?

Compounded semaglutide bypasses brand-name pharmaceutical marketing, manufacturing overhead, and insurance rebate structures. PlexusDx partners with licensed 503A compounding pharmacies, reducing costs to $149 monthly. Compounded formulations are not FDA-approved but operate under pharmacy oversight and clinical provider discretion.

Can I use my insurance to cover compounded semaglutide?

Compounded medications often lack insurance coverage because they are not FDA-approved. However, PlexusDx's direct pricing ($149 monthly) is frequently comparable to or lower than out-of-pocket branded medication costs, even with insurance deductibles or prior authorization denials.

How does the Precision Peptide Genetic Test relate to choosing a semaglutide brand?

The test examines genetic predispositions in peptide pathways (GLP1R, GIPR, FTO, MC4R) that may correlate with metabolic responsiveness to GLP-1 therapy. Results provide biomarker context for your provider conversation but do not predict exact medication response or determine which brand is best—only medical evaluation can.

Semaglutide Brand Name: Understanding Branded vs. Compounded Options